Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become tomorrow’s laggard without continuous development ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

After adjusting for one-time costs, Eli Lilly's adjusted earnings per share (EPS) of $5.32 topped expectations of $5.11. Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

(Reuters) - Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue. Eli Lilly reported net income of $4.41 billion, or $4. ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide later this year, which is a few months earlier than expected. The company ...